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Abstract
Introduction: To assess the effect of canakinumab, a fully human anti-interleukin-1b antibody, on symptoms and
health-related quality of life (HRQoL) in patients with cryopyrin-associated periodic syndrome (CAPS).
Methods: In this 48-week, phase 3 study, patients with CAPS received canakinumab 150 mg subcutaneously at 8-
week intervals. All patients (n = 35) received canakinumab during weeks 1 through 8; weeks 9 through 24
constituted a double-blind placebo-controlled withdrawal phase, and weeks 24 through 48 constituted an open-
label phase in which all patients received canakinumab. Patient and physician assessments of symptoms, levels of
inflammatory markers, and HRQoL were performed.
Results: Rapid symptom remission was achieved, with 89% of patients having no or minimal disease activity on
day 8. Responses were sustained in patients receiving 8-weekly canakinumab. Responses were lost during the
placebo-controlled phase in the placebo group and were regained on resuming canakinumab therapy in the
open-label phase. Clinical responses were accompanied by decreases in serum levels of C-reactive protein, serum
amyloid A protein, and interleukin-6. HRQoL scores at baseline were considerably below those of the general
population. Improvements in all 36-item Short-Form Health Survey (SF-36) domain scores were evident by day 8.
Scores approached or exceeded those of the general U.S. population by week 8 and remained stable during
canakinumab therapy. Improvements in bodily pain and role-physical were particularly marked, increasing by more
than 25 points from baseline to week 8. Therapy was generally well tolerated.
Conclusions: Canakinumab, 150 mg, 8-weekly, induced rapid and sustained remission of symptoms in patients
with CAPS, accompanied by substantial improvements in HRQoL.
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Cryopyrin-associated periodic syndrome (CAPS) is one
of the genetic autoinflammatory disorders that are char-
acterized by recurrent bouts of systemic inflammation,
resulting in fever, rash, and joint pain [1,2]. Most of
t h e s ed i s o r d e r sa r ev e r yr a r e ;C A P Sh a sa ne s t i m a t e d
prevalence of approximately 1 per million, and even the
most common one, familial Mediterranean fever, affects
only approximately 100,000 people worldwide. Identifi-
cation of the genes involved in each disorder has helped
to explain why the various conditions have similar mani-
festations. They all appear to result, directly or indir-
ectly, in overproduction of interleukin-1b (IL-1b), a key
pro-inflammatory cytokine that regulates innate immune
responses [1,2].
CAPS comprises a spectrum of disease from the mildest
form, familial cold autoinflammatory syndrome (FCAS),
through Muckle-Wells syndrome (MWS), to the most
severe form, chronic infantile neurologic cutaneous and
articular syndrome (CINCA), also known as neonatal-
onset multisystem inflammatory disease (NOMID). CAPS-
related symptoms can have a major impact on a patient’s
quality of life [3], which can be further affected by delayed
diagnosis and inappropriate treatment because of poor
recognition of this rare disease by healthcare professionals.
Identification of the mutations involved in each of the dis-
orders has helped establish FCAS, MWS, and NOMID as
different forms of a single disease. All three disorders are
associated with mutations in the NLRP3 gene. This
encodes NALP3, a key component of the inflammasome
complex that regulates the production of IL-1b [1,2]. The
mutations present in patients with CAPS lead directly to
overproduction of IL-1b;i no n es t u d yI L - b levels were
found to be approximately fivefold higher in patients with
CAPS than in healthy individuals [4]. An open-label phase
2 study has shown that canakinumab–which binds selec-
tively to IL-1b, thus potently inhibiting its activity–pro-
duces rapid, complete, and sustained responses in adults
and children with CAPS [5]. Furthermore, a double-blind,
placebo-controlled, randomized withdrawal study has
shown that 8-weekly administration of canakinumab to
patients with CAPS produces sustained remission of
symptoms [6].
Here we report further data from the double-blind,
placebo-controlled, randomized withdrawal study, con-
cerning the impact of canakinumab therapy on the indi-
vidual symptoms of CAPS and on health-related quality
of life (HRQoL).
Materials and methods
Study design
The study was approved by local independent ethics
committees and was conducted in accordance with the
ethical principles laid down in the Declaration of Hels-
kini. As reported elsewhere [6], the study consisted of
three parts (Additional file 1: Supplementary Figure 1).
In part 1, all patients received open-label treatment with
a single dose of canakinumab to assess response during
the following 8 weeks. Part 2 was a double-blind with-
drawal period, in which patients who showed a complete
response in part 1 were randomly assigned to receive
canakinumab or placebo every 8 weeks for up to 24
weeks. At the end of part 2 or on relapse, patients
immediately entered part 3, an open-label treatment
period in which they received canakinumab every 8
weeks for a minimum of 16 weeks to make a total study
duration of 48 weeks. Canakinumab was administered at
a dose of 150 mg [or 2 mg/kg body weight for patients
≤40 kg]. This clinical trial was registered with http://
www.clinicaltrials.gov (registration number:
NCT00465985).
Patients
The study enrolled patients aged 4 to 75 years with
CAPS associated with an NLRP3 mutation. Patients had
t oh a v eab o d yw e i g h to f≥ 15 kg but < 100 kg, and all
patients entering the study or their parents gave written
informed consent. Details of exclusion criteria are
described elsewhere [6].
Assessments of disease activity, definitions, and outcome
measures
At screening and follow-up visits, physicians assessed
global disease activity and each of the following symp-
toms by using a 5-point scale (absent, minimal, mild,
moderate, or severe): urticarial skin rash, arthralgia,
myalgia, headache/migraine, conjunctivitis, fatigue or
malaise, and other symptoms related or unrelated to
CAPS. Blood samples were collected at screening and
specified time points for measurement of concentrations
of C-reactive protein (CRP), serum amyloid-A protein
(SAA), and interleukin-6 (IL-6), and for assessment of
hematologic and biochemical markers.
Patients performed a global assessment of their symp-
toms (rating whether their symptoms were absent, mini-
mal, mild, moderate, or severe) and assessments of the
following individual symptoms [assessing whether they
had any of the following symptoms and rating symp-
toms by using a 5-point scale (absent, minimal, mild,
moderate, or severe): fever/chills, skin rash, joint/muscle
pain, eye discomfort/redness, fatigue, headache, and
other symptoms]. Scores were recorded daily for days 1
through 15 of part 1 and weekly thereafter. Adverse
events (AEs) were recorded throughout the study, and
patients were asked at each study visit whether they had
experienced injection-site reactions.
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physician global assessment of disease activity that was
minimal or absent, with skin rash that was minimal or
absent, and serum values of CRP and/or SAA in the
normal range. Patients were eligible for entry into part 2
if they had a complete response to canakinumab by day
15 without relapse by week 8. The upper limit of normal
(ULN) for CRP and SAA was 10 mg/L.
Assessment of health-related quality of life
HRQoL was assessed at baseline and at specified time
points, by using the following patient-reported outcome
instruments in adults (that is, older than 17 years): the
functional assessment of chronic illness therapy-fatigue
(FACIT-F) [7,8]; the 36-item Short Form Health Survey
(SF-36) standard version [9,10]; and the health assess-
ment questionnaire (HAQ) [11]; and the Child Health
Questionnaire, Parent Form 28 (CHQ-PF28) in pediatric
patients (that is, younger than 17 years) [12]. The
FACIT-F questionnaire evaluates general health status,
with fatigue as a key component. It is scored from 0 to
52, with a higher score indicating less fatigue. SF-36 is a
36-item questionnaire that measures the impact of dis-
ease on overall quality of life and consists of eight indi-
vidual domains that can be grouped to derive a
physical-component summary score (domain names:
physical functioning, PF; role-physical, RF; bodily pain,
BP; and general health, GH) and a mental-component
summary score (domain names: vitality, VT; social func-
tioning, SF; role-emotional, RE; and mental health, MH).
Scores range from 0 to 100, with 0 representing the
worst possible health, and 100 representing perfect
health. The HAQ assesses a patient’s physical ability,
functional status, and quality of life through 20 ques-
tions concerning difficulty in performing eight common
activities of daily living. Patients choose from four
response categories with scores of 0 to 3, ranging from
“without any difficulty” (0) to “unable to do” (3). The
CHQ-PF28 is designed for use in children aged 5 to 17
years and is completed by the parent or guardian. This
instrument rates HRQoL on a scale from 0 to 100, with
values greater than 50 indicating a better HRQoL than
that of the normal child in the United States.
Data analysis
Analysis of data for clinical response was based on an
intent-to-treat population including all patients who
received at least one dose of study drug, entering each
p a r to ft h es t u d y .D a t af o rC R Pa n dS A Aw e r ea n a -
lyzed for all patients entering part 2 of the study. Data
for IL-6 and HRQoL were analyzed for all patients
with evaluable data. Change from baseline for FACIT
score, SF-36 PCS, SF-36 MCS, and HAQ score were
analyzed by using t tests. As these were secondary end
points, no adjustments for multiplicity were done in
the analyses.
Results
Patients and disease characteristics
As reported previously [6], 35 patients enrolled in part 1
of the study; 34 (97.1%) achieved a complete response
to canakinumab at the end of part 1 (see Additional file
1: Supplementary Figure 2). Of these, 31 patients
entered part 2. Responses were maintained during part
2 in all 15 patients (100%) randomized to canakinumab,
after which they entered part 3. Of the 16 patients ran-
domized to placebo, 13 (81.3%) relapsed during part 2
and so proceeded early to part 3. All 31 patients who
entered part 2 also entered part 3. Of these, 29 (93.5%)
completed the study: one patient withdrew considering
the therapeutic response to be unsatisfactory, and a sec-
ond patient withdrew owing to an AE.
As described previously [6], the study included five
pediatric patients (17 years or younger), and approxi-
mately two thirds were girls (also see Additional file 1:
Supplementary table). The study was designed to enroll
patients with MWS (representing mid-spectrum CAPS),
but some patients had more-severe disease (overlapping
MWS/NOMID). Approximately half of patients (n =1 7 ;
48.6%) had previously received anakinra, and nine
(25.7%) had previously received canakinumab; 11
patients had not previously received anti-IL-1b therapy.
Medical conditions probably related to CAPS were
noted at baseline in many patients, including deafness/
impaired hearing (n = 26; 74.3%), arthralgia (n = 31;
88.6%), conjunctivitis (n = 31; 88.6%), urticarial skin
rash (n = 29; 82.9%), headache (n = 25; 71.4%), fatigue
(n = 24; 68.6%), myalgia (n =1 9 ;5 4 . 3 % ) ,p y r e x i a( n =
17; 48.6%), depression (n = 7; 20.0%), uveitis (n =4 ;
11.4%), and amyloidosis (n = 2; 5.7%). According to phy-
sicians, most patients had moderate or severe disease
activity (Table 1).
Response to therapy
Clinical response
A rapid response to canakinumab was seen in part 1,
according to physician and patient assessments. By day
8 (the first assessment), physicians assessed disease
activity as absent or minimal in 31 (88.6%) patients, and
t h i sr e s p o n s ew a sm a i n t a i n e da tt h ee n do fp a r t1( F i g -
ure 1a). Similarly, by day 8, 27 (81.8%) patients rated
their symptoms as being absent or minimal, and this
response was maintained at the end of part 1(Figure 1b).
Ratings for individual symptoms related to CAPS also
showed a rapid improvement in response to canakinu-
mab therapy during part 1. By day 8, physicians rated
symptoms of arthralgia, myalgia, headache/migraine, and
skin rash to be minimal or absent in more than 90% of
Koné-Paut et al. Arthritis Research & Therapy 2011, 13:R202
http://arthritis-research.com/content/13/6/R202
Page 3 of 9patients, and conjunctivitis and fatigue were absent or
minimal in more than 80% of patients (Figure 1a).
Responses were maintained during part 1, with symp-
toms being rated as absent or minimal at the end of
part 1, in more than 95% of patients, for arthralgia,
myalgia, headache/migraine, and skin rash, and in more
than 85% of patients for conjunctivitis and fatigue/
malaise. Similarly, more than 80% of patients rated their
individual symptoms as being absent or minimal by day
8, and response rates were similar at the end of part 1
(1b).
During part 2 of the study, responses were maintained
in patients randomized to canakinumab, according to
physician and patient global assessments; disease activity
was rated as absent or minimal in 100% of patients,
according to the physician assessment and in 66.7% of
patients according to patient assessments. In addition,
physicians rated individual CAPS-related symptoms as
absent or minimal in more than 85% of patients at the
end of part 2. By contrast, treatment responses were lost
during the course of part 2 in patients randomized to
placebo; at the end of part 2, physicians rated disease
activity as absent or minimal in four (25%) patients in
the placebo group, and symptoms as absent or minimal
in four (25%) patients for fatigue/malaise, eight (50.0%)
for conjunctivitis and skin rash, 10 (62.5%) for
Table 1 Severity of CAPS-related symptoms at baseline
Symptom
severity
n (%)
Physician global
assessment
n =3 5
Patient global
assessment
n =3 1
Physician assessment
Skin
rash
n =3 5
Arthralgia
n =3 5
Myalgia
n =3 5
Headache/
migraine
n =3 5
Conjunctivitis
n =3 5
Fatigue/
migraine
n =3 5
Absent 0 4 (12.9) 4 (11.4) 10 (28.6) 15
(42.9)
15 (42.9) 5 (14.3) 4 (11.4)
Minimal 2 (5.7) 6 (19.4) 6 (17.1) 5 (14.3) 4 (11.4) 2 (5.7) 8 (22.9) 2 (5.7)
Mild 7 (20.0) 8 (25.8) 9 (25.7) 10 (28.6) 8 (22.9) 9 (25.7) 11 (31.4) 7 (20.0)
Moderate 22 (62.9) 9 (29.0) 15
(42.9)
7 (20.0) 8 (22.9) 3 (8.6) 8 (22.9) 14 (40.0)
Severe 4 (11.4) 4 (12.9) 1 (2.9) 3 (8.6) 0 6 (17.1) 3 (8.6) 8 (22.9)
Figure 1 Physicians’ (a) and patients’ (b) assessments
a of disease activity and individual symptoms over the study.
aGlobal disease
activity and symptoms were assessed by using a 5-point scale. *n = 33 for end of part 1.
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myalgia. On resuming canakinumab therapy in part 3,
patients randomized to placebo in part 2 again showed
remission of symptoms: at week 8 in part 3, individual
symptoms were rated as absent or minimal in more
than 85% of patients, and physicians rated all patients as
having no or minimal disease activity. At the end of part
3, physicians rated disease activity as absent or minimal
in 30 (96.8%) patients, and 26p a t i e n t s( 8 6 . 7 % )r a t e d
their symptoms as absent or minimal.
Suppression of inflammation
Median IL-6 levels decreased over the course of part 1
from 4.1 pg/ml at baseline to 1.6 pg/ml (canakinumab
group) and 2.3 pg/ml (placebo group) at the end of part
1 (Figure 2a). In the canakinumab group, median IL-6
levels remained low at the end of part 2 (1.7 pg/ml) and
at the end of part 3. In contrast, in the placebo group,
median IL-6 levels increased over part 2 (after receiving
placebo) to 5.2 pg/ml at the end of part 2 and decreased
after resumption of canakinumab therapy in part 3. As
reported previously, median CRP levels were signifi-
cantly elevated above ULN at baseline, normalized at
the end of part 1, and remained below the ULN for the
canakinumab group throughout the study [6]. Median
SAA levels changed similarly over the course of the
study (Figure 2b). In the placebo group, median CRP
and SAA levels increased over the course of part 2, but
decreased to below the ULN in part 3 after resuming
canakinumab. Abnormalities in the hematologic para-
meters were not associated with any increased incidence
or specific type of adverse events.
Impact on HRQoL
At baseline, scores for HRQoL for adults were indicative
of a reduced quality of life compared with the general
U.S. population (Table 2). Over the course of part 1, the
mean FACIT-F score increased significantly from 27.4
at baseline to 40.6 at the end of part 1, an increase of
13.5 (P < 0.05), and was 39.5 at the end of part 3. Thus
Figure 2 Interleukin (IL)-6 (a) and serum amyloid A (SAA) levels (b) over the course of the study by treatment group.
a Data are
presented as median (interquartile range) *1 week after the start of part 1. Upper limit of normal range for SAA was 10 mg/L.
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approached that of the general U.S. population (43.6).
Similarly, the mean SF-36 physical-component summary
( P C S )s c o r ei n c r e a s e df r o m4 1 . 0a tb a s e l i n et o5 1 . 0a t
the end of part 1, an increase of 9.5 (P < 0.05), and was
48.5 at the end of part 3. These values correspond
approximately to those of the general U.S. population
(that is, 50). The mean SF-36 mental-component sum-
mary (MCS) score at baseline was slightly higher than
for the SF-36 PCS score and showed a smaller but still
significant increase over the course of the study from
43.1 at baseline to 47.3 at the end of part 1, up to 48.9
at the end of part 3, an increase of 6.3 (P < 0.05) from
baseline. As for the FACIT-F and SF-36 PCS, the SF-36
MCS score at the end of the study approached that of
the general population (that is, 50). Over the course of
the study, the mean HAQ score decreased from 0.41 at
baseline to 0.17 at the end of part 1 and 0.27 at the end
of the study, indicating a reduction in functional
disability.
At baseline, mean scores for all SF-36 individual
domains were lower than for the U.S. general popula-
tion, and the difference was particularly marked (> 20
points difference) for role-physical, bodily pain, and gen-
eral health (Figure 3). Improvements in mean scores
were evident for all domains by day 8, the first assess-
ment, and were particularly marked (> 9 points) for
role-physical, bodily pain, and general health. Further
improvements were evident over the rest of part 1 of
the study, with mean scores approaching or exceeding
those of the general U.S. population for physical func-
tioning, role-physical, bodily pain, vitality, and social
functioning at the end of part 1. The change from base-
line in mean score at the end of part 1 (for patients who
r e m a i n e di ns t u d ya tt h ee n do fp a r t1 )e x c e e d e d1 0
points for all domains except mental health and
exceeded 25 points for role-physical (26.7) and bodily
pain (29.1). Improvements were sustained throughout
the study during treatment with canakinumab.
HRQoL for the five pediatric patients was assessed by
using the CHQ-PF28. A mean CHQ-PF28 physical sum-
mary score at baseline of 43.4 indicated a reduced qual-
ity of life compared with that expected for normal
children in the United States (that is, 50.0). At the end
of part 1, the mean score was 53.4, and the score was
50.1 at the end of part 3. Mean CHQ-PF28 psychosocial
Table 2 HRQoL scores for adults over the course of the study
U.S. general
population [8,9]
N Baseline n End of
part 1
Change from
baseline
at end of part 1
n End of
part 3
Change from baseline at end
of part 3
FACIT-F 43.6 26 27.4 ± 13.0 24 40.6 ± 12.0 13.5
a 26 39.5 ± 14.7 12.2
a
SF-36
PCS
50.0 23 41.0 ± 9.6 20 51.0 ± 8.3 9.5
a 22 48.5 ± 12.6 8.2
a
SF-36
MCS
50.0 23 43.1 ± 12.3 20 47.3 ± 13.4 3.6 22 48.9 ± 12.4 6.3
a
HAQ NA 26 0.41 ± 0.63 25 0.17 ± 0.40 -0.26
a 26 0.27 ± 0.45 -0.14
Values are expressed as mean ± SD.
ap value < 0.05. FACIT-F, functional assessment of chronic illness therapy- fatigue; HAQ, health assessment questionnaire;
MCS, mental component summary; NA, not available; PCS, physical component summary; SF-36, 36-item Short-Form Health Survey.
Figure 3 SF-36
a domain scores at baseline and at the ends of part 1 and 3 in adults.
aData are presented as the mean.
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ment over the course of the study to 56.1 at the end of
part 3.
Safety and tolerability
As previously reported [6], therapy with canakinumab
for up to 48 weeks was generally well tolerated. Only
two serious AEs were reported: recurrent antibiotic-
resistant lower urinary tract infection and sepsis in one
patient; and vertigo and increased intraocular pressure,
acute glaucoma, and unilateral blindness (complications
of CAPS) in a second patient. Only one patient (the for-
mer) discontinued because of an AE.
Discussion
Most patients included in this study had MWS, a mod-
erately severe form of CAPS, and four patients had
more-severe disease. This was reflected in the severity of
symptoms at baseline, with almost all patients having
arthralgia, conjunctivitis, urticarial skin rash, headache,
and fatigue. In addition, myalgia, pyrexia, and deafness
were reported in more than 50% of patients. In this
study, we report the effects of canakinumab on these
CAPS-related symptoms (except for amyloidosis, for
which the duration of follow-up was insufficient for sig-
nificant changes to be observed, and deafness, for which
the potential for significant recovery of hearing has not
been established). These results are in agreement with
previous reports of the symptoms associated with the
more-severe forms of CAPS [13,14], and give a measure
of how debilitating this disorder is and the need for
effective treatment.
The results of this study indicate that a single dose of
canakinumab induces rapid remission of symptoms in
patients with CAPS; on day 8 (the first assessment), 89%
of patients had no or minimal disease activity, according
to the physician global assessment, and 82% of patients
rated their symptoms as absent or minimal. Rapid
remission was observed for all individual symptoms of
CAPS assessed, and responses were sustained at week 8,
the end of part 1 of the study. Remission of symptoms
was accompanied by suppression of inflammation, as
indicated by decreases in median levels of CRP, SAA,
and IL-6. Furthermore, decreases in platelet counts and
WBC counts and increases in hemoglobin levels were
observed over the course of part 1 of the study, consis-
tent with suppression of chronic inflammation.
Effective suppression of inflammation and symptoms
of CAPS was maintained during treatment with canaki-
numab every 8 weeks during parts 2 and 3 of the study.
At the end of part 3, 97% of all patients had no or mini-
mal disease activity; the median IL-6 level was low (< 1
pg/ml); and CRP and SAA levels were below the ULN.
For patients randomized to placebo, symptoms returned
during part 2, with only four (25%) patients having no
or minimal disease activity at the end of part 2. In addi-
tion, median IL-6, CRP, and SAA levels increased over
the course of part 2. On resuming canakinumab in part
3, remissions were regained in all patients from the pla-
cebo group, and CRP and SAA levels returned to levels
similar to those seen in patients randomized to canaki-
numab in part 2.
CAPS can have a profound impact on HRQoL, as was
previously demonstrated in a study involving in-depth
interviews with patients with FCAS, the mildest form of
this disorder [3]. In this study in patients with FCAS,
patients reported that their disease had affected their
employment, with one third reporting that they had left
their job because of the need to accommodate their
condition, and more than 95% reported to have limited
participation in or avoided outdoor activities and sports.
Subjects also reported that their disease had adverse
effects on social activities, including socializing and per-
sonal relationships.
In our study, we used validated questionnaires to
assess in detail the impact of CAPS on HRQoL in pedia-
tric and adult patients, and the changes in HRQoL
observed in response to canakinumab therapy. At base-
line, SF-36 PCS and MCS, as well as FACIT-F scores,
were all below those of the U.S. general population, as
we previously reported for a phase 2 study with canaki-
numab [15]. In addition, HRQoL scores for our patient
population were comparable to or well below those
reported for patients with musculoskeletal diseases,
including rheumatoid arthritis, gout, osteoporosis, and
fibromyalgia, in a recent survey of the Dutch general
population [16]. Results suggest that the individual SF-
36 domains most affected by CAPS in adults are role-
physical, bodily pain, and general health, as would be
expected from the nature of the symptoms.
Within 8 days of receiving canakinumab, improve-
ments were evident in all SF-36 domains and especially
in those that were more than 20 points lower than
those of the general U.S. population at baseline. This is
in agreement with the rapid remission of symptoms
observed in this study. Eight weeks after receiving the
first dose of canakinumab, scores for FACIT-F, SF-36
PCS, and SF-36 MCS approached or exceeded scores for
the U.S. general population, and improvements were
mostly sustained throughout therapy with canakinumab.
Moreover, further improvements in scores for all the
SF-36 individual domains were observed at 8 weeks
after the dose, compared with day 8. These results are
in agreement with those reported for the phase 2 study,
in which scores for SF-36 PCS, SF-36 MCS, and FACIT-
F all approached or exceeded those of the general popu-
lation by 5 weeks after the dose, and considerable
improvements over baseline for all measures were
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functional disability were also observed over the course
of the study.
HRQoL results for the five pediatric patients included
in the present study also demonstrated an improvement
o v e rt h ec o u r s eo ft h es t u d y .I nt h e s ep a t i e n t s ,t h ep h y -
sical component of HRQoL was well below that
expected for healthy children at baseline and exceeded
t h a to fh e a l t h yc h i l d r e na tt h ee n do fp a r t1a n da tt h e
end of the study. Although these data are based on only
a small patient population, they suggest that the HRQoL
benefits reported for adults are also achieved in pediatric
patients.
As reported previously [6], the results of this study
indicate that canakinumab is generally well tolerated
and is not associated with an increased risk of any parti-
cular AE, other than a slightly increased risk of infec-
tions. Only one patient discontinued the study owing to
AEs, and only two serious AEs were reported during the
course of the study. Because it is envisaged that patients
with CAPS will require life-long therapy, long-term fol-
low-up of patients treated with canakinumab is required
to assess more fully the safety profile of this therapy.
This study has a number of limitations. First, the phy-
sician and patient global assessments and assessments of
the individual symptoms used are not standardized, and
hence results cannot be compared with those from
other studies that have used different measures. Second,
symptoms were assessed on a 5-point scale, which may
bias results because it is difficult to detect small varia-
tions by using such a scale. Third, the patient’s and phy-
sician’s assessments of severity of symptoms scales are
not validated instruments in this disease, which might
have led to the differences in results observed between
the two at baseline.
The dramatic resolution of symptoms and improve-
ments in HRQoL observed in this study in patients with
CAPS is tremendously encouraging and raises the possi-
bility that IL-1b blockade may also benefit patients with
other hereditary autoinflammatory disorders in which
overproduction of IL-1b is implicated in the pathology.
This is supported by promising results that have been
reported for IL-1b blockade in individual patients with
various autoinflammatory disorders and warrants further
investigation [17].
Conclusions
In summary, the results reported here provide further
evidence to indicate that canakinumab induces rapid
remission of clinical symptoms of CAPS and suppres-
sion of markers of inflammation after administration of
a single dose. Remissions were sustained with 8-weekly
dosing and led to considerable improvements in HRQoL
scores, which approached or exceeded those of the U.S.
general population at 8 weeks after the dose and were
maintained during canakinumab therapy. Therapy was
generally well tolerated, and no immunogenicity was
observed. Long-term follow-up of patients is required to
confirm the favorable safety profile reported in this 48-
week study, and follow-up of children during the next
decade will help to determine whether canakinumab
therapy can prevent the development of the neurologic
complications associated with this disorder.
Additional material
Additional file 1: Supplementary file 1: The file contains
supplementary information on patient’s demographics, study design, and
patient’s disposition. The file contains one table: Demographics and
baseline disease characteristics. showing patients ages, sex, types of
NLRP3 mutations and previous anti IL-1 treatments. Supplementary
Figure 1. Study design: showing in details the three parts of the study:
part 1, open-label 8 weeks; part 2, withdrawal period, double-blinded
placebo-controlled study; and part 3, open-label period. Supplementary
Figure 2. Patient disposition: showing the distribution of patients from
assessment eligibility to enrollment, and then through different phases of
treatment and study termination.
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